当前位置: 首页 > 期刊 > 《中国实用医药》 > 2014年第36期 > 正文
编号:12706430
依帕司他联合α—硫辛酸治疗糖尿病周围神经病变(2)
http://www.100md.com 2014年12月25日 熊伟华
第1页

    参见附件。

     参考文献

    [1]Ito A, Ishii-Nozawa R, Ibuki C, et al. Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course. Yakugaku Zasshi, 2009, 129(10):1239-1247.

    [2]王国凤, 徐宁, 尹冬, 等. 糖尿病周围神经病变的治疗新进展. 中国全科医学, 2012(15):1661-1667.

    [3]刘磊, 邵政一.神经再生素对糖尿病大鼠在周围神经病变治疗作用研究.南通大学学报(医学版), 2007, 27(2):103-105.

    [4]Ohmura C, Watada H, Azuma K, et al. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes . Endocr J, 2009, 56(1):149-156.

    [5]Androne L, Gavan NA, Veresiu IA, et al. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo, 2000, 14(2):327-330.

    [6]Coppey LJ, Gellett JS, Davidson EP, et al. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res, 2003, 37(1):33-40.

    [7]Garrent NE, Malcanlgio M, Dewhurst M, et al. Alpha Lipoic acid Corrects neuropeptide deficits in diabetic tats via induction of trophic support. Neurosci Lett, 1997, 222(3):191-194.

    [8]Kawai T, Takei I, Tokui M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N((ε)-carboxymethyl lysine. Joumal of Diabetes and Its Complications, 2010, 24(6):424-432.

    [收稿日期:2014-09-01]

您现在查看是摘要介绍页,详见PDF附件